Interferon Responses in Eczema Herpeticum

Sponsor

National Institute of Allergy and Infectious Diseases

Information provided by

National Institute of Allergy and Infectious Diseases

ClinicalTrials.gov Identifier:

NCT01429311

Purpose

Atopic dermatitis (AD) is a chronic skin disorder characterized by recurrent viral skin infections. Some individuals with AD can get eczema herpeticum (disseminated herpes simplex infection). Interferon (IFN)-γ plays a critical role in the innate and acquired immune responses and has been shown to be significantly decreased after stimulation with HSV ex vivo. The purpose of this study is to determine if deficient IFN-γ induction leads to susceptibility to HSV infection in ADEH+ patients.

Eligibility

Ages Eligible for Study:           6 Years to 65 Years

Genders Eligible for Study:     Both

Accepts Healthy Volunteers: Yes

 

Criteria

Inclusion Criteria:

History of AD with or without eczema herpeticum as diagnosed using the Atopic Dermatitis Research Network (ADRN) Standard Diagnostic Criteria OR who are non-atopic as diagnosed using the ADRN Standard Diagnostic Criteria.

Exclusion Criteria:

Systemic illness not being studied (eg. HIV, lupus)

Active systemic malignancy (other than uncomplicated non-melanoma skin cancer)

Skin disease other than AD that would impact the barrier function (eg. psoraisis, bullous disease)

First degree relative in study

Deemed not eligible by investigator

 

Locations

Denver, Colorado

Principal investigator

Donald Leung, MD, PhD (National Jewish Health)

For more information please visit http://clinicaltrials.gov/ct2/show/study/NCT01429311?term=eczema&rank=12